Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT-FFR Trial.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 30 4 2022
medline: 20 5 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Autopsy studies have established that thin-cap fibroatheromas (TCFAs) are the most frequent cause of fatal coronary events. In living patients, optical coherence tomography (OCT) has sufficient resolution to accurately differentiate TCFA from thick-cap fibroatheroma (ThCFA) and not lipid rich plaque (non-LRP). However, the impact of OCT-detected plaque phenotype of nonischemic lesions on future adverse events remains unknown. Therefore, we studied the natural history of OCT-detected TCFA, ThCFA, and non-LRP in patients enrolled in the prospective multicenter COMBINE FFR-OCT trial (Combined Optical Coherence Tomography Morphologic and Fractional Flow Reserve Hemodynamic Assessment of Non-Culprit Lesions to Better Predict Adverse Event Outcomes in Diabetes Mellitus Patients). In the COMBINE FFR-OCT trial, patients with diabetes and ≥1 lesion with a fractional flow reserve >0.80 underwent OCT evaluation and were clinically followed for 18 months. A composite primary end point of cardiac death, target vessel-related myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina was evaluated in relation to OCT-based plaque morphology. A total of 390 patients (age 67.5±9 years; 63% male) with ≥1 nonischemic lesions underwent OCT evaluation: 284 (73%) had ≥1 LRP and 106 (27%) non-LRP lesions. Among LRP patients, 98 (34.5%) had ≥1 TCFA. The primary end point occurred in 7% of LRP patients compared with 1.9% of non-LRP patients (7.0% versus 1.9%; hazard ratio [HR], 3.9 [95% CI, 0.9-16.5]; Among diabetes patients with fractional flow reserve-negative lesions, patients carrying TCFA lesions represent only one-third of LRP patients and are associated with a high risk of future events while patients carrying LRP-ThCFA and non-LRP lesions portend benign outcomes. URL: https://www. gov; Unique identifier: NCT02989740.

Sections du résumé

BACKGROUND
Autopsy studies have established that thin-cap fibroatheromas (TCFAs) are the most frequent cause of fatal coronary events. In living patients, optical coherence tomography (OCT) has sufficient resolution to accurately differentiate TCFA from thick-cap fibroatheroma (ThCFA) and not lipid rich plaque (non-LRP). However, the impact of OCT-detected plaque phenotype of nonischemic lesions on future adverse events remains unknown. Therefore, we studied the natural history of OCT-detected TCFA, ThCFA, and non-LRP in patients enrolled in the prospective multicenter COMBINE FFR-OCT trial (Combined Optical Coherence Tomography Morphologic and Fractional Flow Reserve Hemodynamic Assessment of Non-Culprit Lesions to Better Predict Adverse Event Outcomes in Diabetes Mellitus Patients).
METHODS
In the COMBINE FFR-OCT trial, patients with diabetes and ≥1 lesion with a fractional flow reserve >0.80 underwent OCT evaluation and were clinically followed for 18 months. A composite primary end point of cardiac death, target vessel-related myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina was evaluated in relation to OCT-based plaque morphology.
RESULTS
A total of 390 patients (age 67.5±9 years; 63% male) with ≥1 nonischemic lesions underwent OCT evaluation: 284 (73%) had ≥1 LRP and 106 (27%) non-LRP lesions. Among LRP patients, 98 (34.5%) had ≥1 TCFA. The primary end point occurred in 7% of LRP patients compared with 1.9% of non-LRP patients (7.0% versus 1.9%; hazard ratio [HR], 3.9 [95% CI, 0.9-16.5];
CONCLUSIONS
Among diabetes patients with fractional flow reserve-negative lesions, patients carrying TCFA lesions represent only one-third of LRP patients and are associated with a high risk of future events while patients carrying LRP-ThCFA and non-LRP lesions portend benign outcomes.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT02989740.

Identifiants

pubmed: 35485232
doi: 10.1161/CIRCINTERVENTIONS.121.011728
doi:

Substances chimiques

Lipids 0

Banques de données

ClinicalTrials.gov
['NCT02989740']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e011728

Auteurs

Enrico Fabris (E)

Cardiovascular Department, University of Trieste, Italy (E.F.).

Balasz Berta (B)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.B.).
Isala Hartcentrum, Zwolle, the Netherlands (B.B., R.S.H.).

Tomasz Roleder (T)

Department of Cardiology, Hospital Wroclaw, Poland (T.R.).

Renicus S Hermanides (RS)

Isala Hartcentrum, Zwolle, the Netherlands (B.B., R.S.H.).

Alexander J J IJsselmuiden (AJJ)

Department of Cardiology, Amphia Ziekenhuis, Breda, the Netherlands (A.J.J.I.).

Floris Kauer (F)

Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands (F.K.).

Fernando Alfonso (F)

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain (F.A.).

Clemens von Birgelen (C)

Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands (C.v.B.).
Technical Medical Centre, Health Technology and Services Research, University of Twente, Enschede, Netherlands (C.v.B.).

Javier Escaned (J)

Hospital Clínico San Carlos, Madrid, Spain (J.E.).

Cyril Camaro (C)

University Medical Center Radboudumc, Nijmegen, the Netherlands (C.C.).

Mark W Kennedy (MW)

Beaumont Hospital, Dublin, Ireland (M.W.K.).

Bruno Pereira (B)

INCCI- Haertz Zenter, Luxembourg (B.P.).

Michael Magro (M)

Tweesteden Ziekenhuis, Tilburg, the Netherlands (M.M.).

Holger Nef (H)

Universitätsklinikum, Gießen/Marburg, Germany (H.N.).

Sebastian Reith (S)

Uniklinik RWTH, Aachen, Germany (S.R.).

Magda Roleder-Dylewska (M)

Department Medical University of Silesia, Katowice, Poland (M.R.-D., P.G., W.W., E.K.).

Pawel Gasior (P)

Department Medical University of Silesia, Katowice, Poland (M.R.-D., P.G., W.W., E.K.).

Krzysztof Malinowski (K)

Department of Bioinformatics and Telemedicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland (K.M.).

Giuseppe De Luca (G)

Eastern Piedmont University, Novara, Italy (G.D.L.).

Hector M Garcia-Garcia (HM)

Interventional Cardiology, MedStar Washington Hospital Center, Washington, D.C. (H.M.G.-G.).

Juan F Granada (JF)

Cardiovascular Research Foundation, New York (J.F.G.).
Columbia University Medical Center NYC, NY (J.F.G.).

Wojciech Wojakowski (W)

Department Medical University of Silesia, Katowice, Poland (M.R.-D., P.G., W.W., E.K.).

Elvin Kedhi (E)

Department Medical University of Silesia, Katowice, Poland (M.R.-D., P.G., W.W., E.K.).
Erasmus Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium (E.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH